You are here:

Archived: ranolazine (Ranexa)

Advice

following a second resubmission

ranolazine (Ranexa®) is not recommended for use within NHS Scotland.

Indication under review: as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line antianginal therapies (such as beta-blockers and/or calcium antagonists).

When added to standard doses of antianginal drugs, ranolazine increased exercise duration at trough drug levels compared with placebo after 12 weeks treatment.  Although significant the effect size was modest.

The submitting company did not present a sufficiently robust clinical and economic case to gain acceptance by SMC.
 

Drug Details

Drug Name: ranolazine (Ranexa)
SMC Drug ID: 565/09
Manufacturer: A Menarini Pharmaceuticals UK Ltd
Indication: as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line anti-anginal therapies (such as beta-blockers and/or calcium channel blockers [CCB]) [1].
BNF Category:
Sub Category: 2.6 Nitrates calcium-channel blockers and other antianginal drugs
Submission Type: Resubmission
Status: Not Recommended
Date Advice Published: 16 January 2012

Current Advice

IRP 12 November 2012

Archived Advice

Resubmission 13 December 2010
Full submission 7 September 2009

Back